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Miguel Waterhouse,1 Dietmar Pfeifer,2 Milena Pantic,2 Florian Emmerich,3
Hartmut Bertz,1 J€urgen Finke1Molecular pathogenesis of relapse after allogeneic hematopoietic cell transplantation is poorly understood.
Data regarding relapse mechanisms after transplantation is scarcely available. We investigated genomic
aberrations (GAs) in 21 patients undergoing related and unrelated HLA-matched transplantation in leukemic
blasts before transplant and at relapse after transplantation. We found a higher number of GAs after trans-
plantation, suggesting increased genomic instability during relapse. Two of 21 patients showed a large homo-
zygous region spanning the whole HLA-locus on chromosome 6p in the relapse sample. In both patients
sequence-based HLA typing of the blasts revealed a loss of the patient-specific allele at the mismatched locus
leading to homozygosity for the HLA haplotype shared by the patient and the donor. In addition, GAs were
found in critical regions such as 12p13, 13q12.2, and 17p13. Our results suggest that escape from immuno-
logic surveillance may be a relevant mechanism of relapse after transplantation in patients with GAs on chro-
mosome 6p. A combination of continuous immunologic pressure mediated by donor T cells and clonal
evolution of myeloid leukemia may result in acquired GAs after transplantation.
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Allogeneic hematopoietic cell transplantation
(HCT) is themost effective curative therapy in patients
with hematologic malignancies such as acute myeloid
leukemia (AML) and myelodysplastic syndromes [1-3].
Despite improvements in the clinical management,
relapse from the original disease is still 1 of the main
causes of treatment failure [4]. The World Health
Organization uses several variables to categorize hema-
tologic diseases [5]. However, these classifications are
not fully predictive of response to treatment [6].
Furthermore, the aforementioned approach gives no
insight into the relapse mechanisms. In addition, ac-
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(\5 Mb) genomic aberrations (GAs) are not detectable
with conventional cytogenetics and therefore are not
taken in account for risk prognosis. Recently, a new
reporting system that combines cytogenetic and
molecular genetic data has been proposed with the
aim of a better understanding of AMLmolecular path-
ogenesis [7].
Despite the identification of new and prognostic
markers inAMLpatients, available data on the influence
of genomic changes in relapsed patients after allogeneic
HCT is scarce, in particular, in HLA identical trans-
plantation. Comparing preconditioning to relapse sam-
ples of the malignancy has the potential to determine
possible causes of resistance [8]. After transplantation,
selective pressure mediated by donor T cells together
with clonal evolution of the underlying disease can
result in genomic changes of different chromosomal
regions, such as the HLA region on chromosome 6p,
as shown by several animal models and in haploidentical
transplantation [9-12]. Alterations in the genome after
transplantation can also result in a change of the
zygosity status of mutated genes like JAK2 and
FLT3-ITD, leading to homozygosity or hemizygosity,
a condition that carries a worse prognosis [13,14].
Furthermore, the acquired genomic changes, detected
after allogeneic HCT, can pinpoint chromosomal
regions that may contain novel mutational targets
potentially involved in the relapse.
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Hematopoietic Cell TransplantationHere we examined genome-wide DNA copy num-
ber changes, before transplantation and at relapse, in
patients with de novo AML or secondary AML
who have undergone allogeneic HCT from matched
related and unrelated donors with the aim to provide
some insights in possible relapse mechanisms after
allogeneic transplantation.MATERIALS AND METHODS
Patients and Transplantation Procedure
The study group consisted of 21 patients with a
diagnosis of de novo or secondary AML who have re-
lapsed after allogeneic HCT. Clinical characteristics
from the patients included in the study are described
in Table 1. All patients received nonmanipulated
recombinant human (rhu)-granulocyte-colony stimu-
lated factor-mobilized peripheral blood stem cells
except for patient 17, who received bone marrow as
a graft source. Leukemic blasts were obtained either
before induction chemotherapy (patients 2, 7, 13) or
before transplantation after induction failure. As pre-
parative conditioning regimen patients up to the age
of 50 years received a standard protocol that included
busulfan 3.2 mg/kg/day (days 27 and 24) and cyclo-
phosphamide 60mg/kg/day (days23 and22). Patients
.50 years received a reduced toxicity conditioning reg-
imen consisting of fludarabin 30 mg/m2/day (days 27
and 24), BCNU 150 mg/m2/day (days 27 and 26),
and melphalan 110 mg/m2/day (day 24). Graft-vs-
host prophylaxis for related and unrelated donors was
performed as previously described [3,15]. Patients and
their related or unrelated donors were matched for
HLA-A, HLA-B, and HLA-C by low-resolution
(2-digit) DNA typing except for patients 6, 8, 13, 14,
and 19, which were typed by high-resolution analysis
(4 digit). All patients were DNA-typed by high resolu-
tion for the class II alleles, DRB1, andDQB1. Patient 6
was also typed for DPB1. Written informed consent
was given by the patients according to the protocol ap-
proved by the ethics committee of Freiburg University
Medical Center.Isolation of DNA and Single Nucleotide
Polymorphism (SNP) Array Analysis
Leukemic blasts were selected for CD34 to purity
$80%, using CD34microbeads andmagnetic-assisted
cell sorting (Miltenyi Biotec, Bergisch Gladbach,
Germany). We have previously standardized the ge-
nome wide profiling methodology used in the present
study, and it is possible to reliably detect the genotype
of interest when this genotype represents more than
20% to 30% of a genotype mixture [16]. Genomic
DNA was isolated from selected CD 341 leukemic
blasts before and at relapse after allogeneic HCT.The obtained genomic DNA was analyzed using
Genome-Wide Human 250K NspI (patients 1-5, 9,
18-20) and SNP 6.0 Arrays (patients 6-8, 10-17, 21)
(Affymetrix, Santa Clara, CA). GAs such as copy num-
ber gains and losses, as well as regions showing runs of
homozygous SNPs were analyzed with Genotyping
Console 4.0 (Affymetrix). The samples hybridized to
250k NspI arrays were compared against a reference
set of DNA from 50 healthy individuals, whereas the
samples analyzed with SNP 6.0 arrays were compared
against a reference set of 270HapMap-Samples as pro-
vided by the GTC software (Affymetrix). To avoid
overestimation of the number of GAs because of germ-
line polymorphisms copy number abnormalities in the
size range of copy number variants were compared
against entries in the Toronto Database of Genomic
Variants [17] for potential overlap. Trisomies were
considered as gains and monosomies as losses.
Fluorescence in Situ Hybridization (FISH),
Pyrosequencing, and Microsatellite Analysis
Selected leukemic blasts obtained from peripheral
blood or bone marrow of the patients were used for
FISH analysis. The FISH studies were performed
according to manufacturer’s instructions, using the
following probes: EGR1 (5q31), TP53 (17p13.1),
ETV6 (12p13), ATM (11q 22.3), D7Z1 (centromere
of chromosome 7), and D8Z2 (centromere of chromo-
some 8) (Abbott,Wiesbaden, Germany). A total of 200
interphase nuclei were analyzed per patient. Peripheral
blood cells from healthy donors were used as the
positive controls of DNA probes used for FISH. The
detection of the JAK 2 mutation (1849 G.T) was
done by pyrosequencing as described elsewhere [18].
We analyzed the FLT3- internal tandum duplication
(ITD) mutation for the presence of ITD using a mod-
ified polymerase chain reaction as previously described
[19]. The wild-type samples yielded a single product at
approximately 129 bp, whereas the ITD allele varied in
size from 149 bp to 240 bp. For both types of muta-
tions, samples were scored as homozygous if the
proportion of the mutant allele was .50% compared
with the wild-type allele. DNA obtained from
HEL (homozygous for JAK 2 mutation) and MV4-11
(homozygous for FLT3-ITDmutation) cell lines were
included as positive controls.
Hematopoietic chimerism was tested using short
tandem repeats, and the amplification of the highly
polymorphic microsatellite marker YNZ22, in the
17p13.3 region was done as previously described [20].
Sequence-Based HLATyping of Patients
and Donor Samples
Cycle sequencing of exons 2 and 3 of HLA class I
genes was performed using the ProTrans S4 sequenc-
ing kit for HLA class I and for HLA DRB1* (exon 2).
Table 1. Clinical Characteristics of 21 Patients with De Novo AML or Secondary AML Undergoing Allogeneic HCT
Patient # Age Gender Diagnosis HLA-mismatch
Chromosomal Aberrations
Detected at Diagnosis (Number
of Metaphases Analyzed)
Bone Marrow
Blasts at
Transplantation (%)
Type of
Transplant
GVHD
Prophylaxis
Maximal Acute
GVHD (Grade)
Chronic
GVHD
Time to
Relapse
(Days)
1 31 M AML M2 None 46,XY(20) 50 MUD CyA/MTX/ATG 0 Yes 1430
2 61 F AML M5 None 46,XX(20) 8 MUD CyA/MMF/ATG 0 Yes 141
3 65 M AML M5 1DRB1 46,XY(20) 10 MUD CyA/Campath 2 No 369
4 60 F sAML None 46,XX(20) 45 MUD CyA/MMF/ATG 0 No 90
5 35 M AML M2 1C 46,XY(20) 60 MUD CyA/MTX/ATG 3 Yes 221
6 54 M AML M2 None 46,XY(20)* 58 MUD CyA/Campath 2 Yes 412
7 47 M AML M5 None 46,XY† (15) <5 MUD CyA/Campath 0 Yes 1120
8 76 F AML M4 None 46,XX‡(20) 30 MUD CyA/Campath 0 No 158
9 68 M sAML None Complex karyotype(20) 44 MUD CyA/MMF/ATG 0 No 78
10 66 M sAML 1C 46,XY,t(1;4)(p36;q31)(5)§ 90 MUD CyA/Campath 2 Yes 213
11 68 M AML M2 None 47,XY,+8(20)¶ 20 MUD CyA/Campath 0 No 789
12 67 M sAML None 47,XY,+8(20) 25 MRD CyA/Campath 4 No 239
13 45 M AML M4 1B1C Complex karyotype(6)* <5 MUD CyA/Campath 0 Yes 227
14 68 F sAML 1A 1C
1DQB1
46,XX,5q-(13)§ 10 MUD CyA/Campath 1 Yes 217
15 45 M sAML 1C Complex karyotype(16)* 47 MUD CyA/Campath 4 Yes 686
16 52 F AML M4 1B 1DRB1 46,XX,t(6;9)(p23;q34)‡(14) 15 MUD CyA/Campath 0 No 149
17 23 M AML M4 1B 1C 46,XY,t(3;14)(p21;q32)‡(19) 20 MUD CyA/Campath 2 No 355
18 68 M AML M4 None 46,XY,t(6;11)(q27;q23)*(20) 90 MUD CyA/Campath 2 No 418
19 42 M AML M5 None 46,XY,t(9;11)(p22;q23)§(16) 20 MRD CyA/MTX 0 No 108
20 52 F AML M1 1DRB1 46,XX,5q-(17) 55 MUD CyA/Campath 0 No 817
21 70 M sAML None 45,XY,-7(20) 25 MUD CyA/Campath 2 Yes 486
AML indicates acute myelogenous leukemia; HCT, hematopoietic cell transplantation; GVHD, graft-versus-host disease; MUD/MRD, matched unrelated donor/matched related donor; CyA, cyclosporine;
ATG-Fresenius, antilymphocyte human T immunoglobulin (dose: 20 mg/kg/day for 2-3 days); MTX, methotrexate; MMF, mycophenolate mofetil; Campath, alemtuzumab (dose: 10 mg/day for 1-2 days).
Additional mutations detected: *FLT3-ITD negative, †FLT3-ITD and NPM1 mutated ‡FLT3-ITD mutated NPM1 wild type §FLT3-ITD negative NPM1 wild type ¶ JAK2 V617F positive.
Patients #7, 11, 12, and 13 relapsed with the same karyotype. Patients #14 and 19 relapsed with a complex karyotype. No relapse karyotype was available for the rest of the patients.
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Hematopoietic Cell TransplantationFor HLA-DQB1* and HLA-DPB1* the ProTrans S3
and S1 sequencing kit was used according to manu-
facturer’s recommendations respectively (ProTrans
GmbH, Hockenheim, Germany) and as previously
described [21]. Sequences were analyzed using
the sequence pilot software (JSI Medical Systems,
Kippenheim, Germany).
Statistics
For the comparison of qualitative or quantitative
variables without a normal distribution the Mann-
Whitney, Wilcoxon signed-rank test, or Kruskal-
Wallis tests were used. Quantitative variables with
a normal distribution were analyzed with the Student’s
paired t test or Fisher’s exact test in the case of small
numbers. All tests were 2 sided, accepting P # .05 as
indicating a statistically significant difference. Statisti-
cal analysis was performed using the GraphPad
5.0 software (La Jolla, CA).RESULTS
Comparison of Genomic Aberrations between
Pre- and Posttransplantation Samples
Copy number analysis revealed a total of 146 geno-
mic abnormalities in 21 pairs of AML genomes before
allogeneic transplantation and at relapse in patients
diagnosed with de novo AML or secondary AML. In
5 patients (#1, 2, 7, 8, 18) no aberrations were detected
either before or at relapse after transplantation. The
total number of GAs was significantly higher after
transplantation compared with the pretransplant sam-
ples (P\ .05). A mean of 2.3 altered regions per case
(range: 0-19) were detected before transplantation,
wheres at relapse a mean of 4.6 genomic abnormalities
per patient was observed (range: 1-20). Eight of 21 pa-
tients showed 1 or more genomic alterations before
transplantation, whereas in 16 of 21 patients they were
detected only in the relapse sample (Supplementary
Table 1). In general, the frequency of copy number los-
ses was significantly (P\ .05) higher than the frequency
of CN-LOH. In addition, copy number losses were
more common than copy number gains (2.7:1) Genomic
changes were observed in all AML FAB subtypes sam-
ples included in the present study. A comprehensive de-
scription of the acquired GAs is depicted in Table 2.
Within the group of patients without pretransplant
chromosomal aberrations, only in 1 patient a small
deletion on chromosome 14q11.2 (0.5-0.6 Mb) was
observed in the pretransplant sample, which was not
detected by conventional cytogenetics. In contrast, in
the group of patients with abnormal/complex karyo-
type, 6 additional losses and 1 gain were found in 7 pa-
tients. Taking these results together, 17% of GAs were
revealed only by SNP array, in 8 (38%) cases in the
pretransplant samples. In addition, 5 large CN-LOH($11Mb) were detected in 3 patients before transplan-
tation. In 2 patients with normal karyotype and with
FLT3-ITD and NPM1 mutation no GAs were
detected either before or after transplantation. The
mean size of the acquired aberrations was 12.5 Mb
(range: 0.5-72 Mb). There were no significant differ-
ences in the GA size before transplant and at relapse
(12.4 Mb and 12.2 Mb, respectively). The number of
GAs among our patient cohort showed large variations
ranging from 0 to 20 per sample. Shared abnormalities,
found before transplantation and at relapse, were iden-
tified in 8 patients (38%) indicating common clonality.
Conversely, 23 novel losses, 6 CN-LOH regions and
6 gains arose at relapse in 13 patients (62%). All chro-
mosomes showed 1 or more aberrations, with large
differences among the 22 autosomes. However, cer-
tain chromosomes appeared to be affected more fre-
quently. For example, chromosome 2 showed only
2 genomic losses in the posttransplant sample, whereas
chromosome 17 had a total of 8 genomic changes at
the same time point.
Recurrent Genomic Aberrations at Relapse
after Allogeneic HCT
Several recurrent GAs were detected at relapse
after allogeneic HCT. The most common lesion was
trisomy 8 and a deletion in chromosome 12p13, occur-
ring in 4 patients. A recurrent deletion in chromosome
17p13.1 was identified 3 patients in the relapse sample.
We have identified 2 patients with loss of wild-type
FLT3 in the relapse sample after allogeneic HCT. In
1 case it was because of a 17-Mb deletion in 13q
(Figure 1), wherease in the other patient a CN-LOH
involved the whole arm of chromosome 13q.
A very interesting finding in our studywas a large ho-
mozygous region (40 Mb) spanning the HLA-locus on
chromosome 6p, which was identified at relapse in 2 pa-
tients. Sequence-based HLA typing of the blasts from
these patients revealed a loss of the patient-specific allele
at themismatched locus leading to homozygosity for the
HLA haplotype shared by the patient and the donor
(Figure 2 and Supplementary Table 2).
Locus-Specific Validation of Acquired GAs
To confirm the detected CN-LOH and DNA
copy number changes in the allogeneic transplanted
patients, we performed a locus-specific validation anal-
ysis. The FISH analysis of leukemic blasts showed 1
signal for the probes EGR1 (5q31), TP53 (17p13.1),
ETV6 (12p13), and ATM (11q 22.3). The mentioned
regions also showed a hemizygous deletion by SNP
array analysis. The D8Z2 probe revealed 3 signals in
patients with trisomy 8, while the D7Z1 probe
showed only 1 signal in patient 21, both detected by
cytogenetics and with the array platform. One patient
with LOH on the short arm of chromosome 9p24 was
Table 2. Comprehensive Description of Acquired Copy Number Changes, Known Genes in Affected Regions, and Locus-Specific
Validation
ID
Gains Losses CN-LOH
Known Genes ValidationBefore Tx Size Relapse Size Before Tx Size Relapse Size Before Tx Size Relapse Size
3 +8 TYMS FISH Chr.8
18p11.32 2.9
4 15q11.2 37 13q WA FLT3BCL8 ND
5 +4+10 11p WA 11p WA ND
6 9q33.1 1.5 14q11.2 0.6 3q25.1 8.1 6p† 40 HLA† Sequence-based HLA typing
16p13.3 2.6 11p14.3 14
20q12 1.3 18q21 0.8
22q12 1
9 1p 50 2q21.2 2.7 2q21.2 2.7 FISH TP53
3q26.3 11 3q26.3 11 3q25.1 17 3q25.1 17 Microsatellite
10q21.3 9.2 10q21.3 9.2 3q26.3 3.4 3q26.3 3.4 YNZ22
17q12 3.4 17q12 3.4 4q22.3 3.9 4q22.3 3.9 NFKB1¶
4q24 32 4q24¶ 32
4q31.3 39 4q31.3 39
5q21.1 4.7 5q21.1 4.7
5q22.1 3.9 5q22.1 3.9 ARHGAP26‡
5q31.1 36 5q31.1‡ 36
9q12 34 9q12 34
10q23.1 3.8 10q23.1 3.8 ABCC1†
12q24.3 2.5 12q24.3 2.5
16p13.3 22 16p13.3† 22
16q21 11 16q21 11
16q23 7.2 16q23 7.2 TP53#
17p13.1 18 17p13.1# 18
20q11.3 13 20q11.3 13
10 14q11.2 0.5 ND
11 +8 +8 4q24 1.5 4q24 1.5 9p24† 17 9p24 17 JAK2† Pyrosequencing
11q WA JAK2
12 +8 +8 FISH Chr.8
13 11q14.1 4.2 FISH
12p13.3† 21 ETV6† ETV6/TP53
17p13.1 7 Microsatellite
17p12 8 YNZ22
14 11q24.1 11 11q24.1 11 5q14.3 72 5q14.3 72 6p† 40 HLA† Sequence-based HLA typing
19q13 7.4 11q14.1 43 11q14.1‡ 43
11p13 0.9 ATM‡
12p13.31 5.5
15q12 4.6
15q14 4.4
17q23 1
17q21 0.7
19q23.1 1
19q21 0.7
15 +1q 16q WA ND
+6
+10
+13
+16
+21
16 +8 1p36 0.5 13q† WA FLT3† FISH Chr.8, FLT3-ITD
17 22q11.3 0.5 22q11.3 0.5 FLT3-ITD
13q12.2† 17 FLT3†
19 +6 8q24.13 2.1 FISH ETV6, TP53
+8 10p15.1 61
12p13.3† 14 ETV6† Microsatellite
17p13.1‡ 22 TP53‡ YNZ22
20 +11 +11 1q25.1 61 1q25.1 61 17q 18 17q 18 FISH EGR1, ETV6
2q32.1 50 19q 11 19q 11
3p24.3 1.8 3p24.3 1.8
3p21.3 1.5 3p21.3 1.5
3p14.1 11 3p14.1 11
4p15.2 1.1
5q14.3 72 5q14.3† 72 EGR1†
7p21.1 3.9 7p21.1 3.9
7p14.3 13 7p14.3 13
7q WA 7q WA
12p13.3 1.8 12p13.3‡ 1.8 ETV6‡
12p13.2 18 12p13.2 18
18p11.32 2.7
18q21.2 12 18p21.33 41
18q22.2 7.6 18q22.2 7.6
21 8q24.2 2.2 3q26.2 0.7 3q26.2 0.7 FISH Chr.7
+12 -7 -7
CN-LOH indicates copy-neutral loss of heterozygosity; ND, not done; FISH, fluorescence in situ hybridization.
Symbols † ‡ ¶ # indicate known genes and the corresponding physical location.
*Genomic aberrations size is given in megabases (Mb).
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Hematopoietic Cell Transplantationhomozygous for a JAK2 mutation as detected by pyro-
sequencing. Short tandem repeats analysis using the
polymorphic marker YNZ 22 confirmed the allelic
loss of at least 1 allele in the 17 p13.3 region that has
been found in 3 patients. The results of FISH, pyrose-
quencing, microsatellite analysis, and FLT3-ITDmu-
tational status were completely congruent with the
genomic abnormalities detected by the SNP array.
Correlation of GAs with Transplant and
Nontransplant-Related Variables
The patients younger than 60 years (n5 10) at the
time of transplantation, with de novo AML or those
who received a standard conditioning regimen showed
a significant increase in the number of all types of GAs
after transplantation (P\ 0.05).
No significant association was found between ac-
quired genomic changes and reduced-intensity condi-
tioning regimen, karyotype, or acute and chronic
graft-vs-host disease (Table 3). In addition, there was
no significant association between time to relapse or
overall survival and the presence or the number of
acquired GAs (data not shown).DISCUSSION
We performed genome-wide SNP-array analysis
of de novo and secondary AML patients undergoing
related and unrelated allogeneic HCT, who have
relapsed after transplantation. Genomic changes are
not an uncommon finding in adult AML at diagnosis
[22], and they may also be found at relapse after con-
ventional chemotherapy [23]. Although available data
on the influence of genomic changes in relapsed
patients after allogeneic HCT is scarce [8], patients
with de novo AML, under 60 years of age or those
who received a standard conditioning regimen showed
a significantly increase in the number of GA after
transplantation. Because patients\50 years received
a standard conditioning regimen it is not possible to
discriminate the variables age and conditioning regi-
men and their association with an increased number
of GA after transplantation. In a previous study pa-
tients with a karyotype change after transplantation
were significantly younger than those with a stable kar-
yotype [24]. In addition, a higher frequency of cytoge-
netic changes in patients receiving reduced-intensity
conditioning compared with standard chemotherapy
has previously been described, although the difference
did not reach a statistical significance [23]. Of notice,
because of the limited size of our patient cohort the ob-
served associations should be interpreted with caution.
Genome-wide copy number analysis of the AML
transplanted patients showed that 17% of the GAs in
the pretransplant samples were not detected by con-
ventional cytogenetics. Previous studies reporteda range between 38% and 49% of cryptic GAs not de-
tected by conventional karyotyping of AML genomes
paired with normal DNA [25,26]. One caveat of our
study is the lack of paired normal samples, which in
turn, can result in an overestimation of GAs because
of germline polymorphisms. To overcome this
limitation, we excluded genomic changes spanned by
copy number variants present in the Toronto
database of genomic variants, reducing in this way
the likelihood of including germline aberrations. In
addition, we performed locus-specific validation of
the acquired GAs, in several chromosomal regions us-
ing different methods. Finally, GAs present only after
transplantation are very likely to be true acquired so-
matic aberrations. Even though a lower number of
DNA copy number changes was found, compared
with previous reports, cytogenetic and genomic find-
ings in the pretransplant samples showed a high degree
of correlation. Although all the patients included in
this study were high-risk AML with a transplantation
indication, pretransplantation treatment differed
among patients (no treatment vs induction failure).
This could potentially introduce a bias in the analysis
of the pretransplant sample.
The causes of relapse after allogeneicHCT remain
elusive and are poorly understood. Two recent reports
described CN-LOH in chromosome 6p with the loss
of the recipient specific HLA haplotype in patients re-
ceiving anHLAhaploidentical transplantation [11,12].
In these reports the authors suggest that by losing
recipient mismatched HLA alleles, leukemic blasts
may escape from donor’s immunologic surveillance,
which in turn will lead to relapse of the disease.
Villalobos et al. [12] did not find any loss of HLA class
I expression in a HLA-matched HCT setting, and
therefore they suggested that loss of the HLA class I
haplotype at relapse, after transplantation, is uncom-
mon in this type of transplantation setting.
In our study we found the loss of the patient-
specific allele at the HLA-mismatched locus, which
was detected in 2 patients after unrelated allogeneic
stem cell transplantation. In both cases, a 40-Mb
CN-LOHon chromosome 6p was found in the relapse
sample, encompassing the whole HLA locus.
Sequence-based HLA typing of the blasts after relapse
showed the absence of the patient-specific allele at the
mismatched locus in both patients. Interestingly, 1 pa-
tient had a normal chromosome 6p as detected in the
relapse sample before administration of 5 courses of
donor lymphocyte infusion (DLI) (data not shown).
After successful DLI treatment, the patient achieved
complete remission; however, 3 months later she expe-
rienced a relapse of the leukemia. In this last sample,
CN-LOH on chromosome 6p was detected. It can
be speculated, as suggested by others in the context of
haplotransplantation [11,12], that selective pressure
mediated by donor T cells resulted in the appearance
Figure 1. Posttransplant deletion on chromosome 13q12, resulting in a zygosity change in FLT3-ITD mutational status. Copy number profile of chro-
mosome 13 in patient #17 using 250k NspI SNP mapping arrays. Pretransplant sample is represented in green, while leukemic blast at relapse is repre-
sented in blue (A). A log-2 ratio reduction of 17 Mb, between 13q12.2 and 13q14.11 spanning the FLT3 locus (red line) was detected in the posttransplant
sample indicating a deletion as depicted by the copy number change. FLT3-ITD mutational status change after transplantation (B). Wild-type allele was
always detected at approximately 129 bp, whereas the FLT3-ITD mutated allele varied in size from 140 bp to 240 bp. Heterozygous FLT3-ITD mutation
detected in the pretransplant sample, wild-type peak is more than 50% higher than the mutated allele. After transplantation a loss of almost the whole
wild-type peak is detected, resulting in homozygosity for FLT3-ITD mutation.
1456 Biol Blood Marrow Transplant 17:1450-1459, 2011M. Waterhouse et al.of the leukemic clone carrying the CN-LOH in chro-
mosome 6p, facilitating immune escape from the
donor immune system, finally leading to relapse. In
contrast, because CN-LOH in chromosome 6p had
also been described in AML at the time of initial diag-
nosis [27], it will be difficult to discriminate between
GAs associated with immune pressure of transplanta-
tion and those associated with chemotherapy or with
clonal evolution of the disease. Loss of the HLA class
I haplotype posttransplantation in nonhaploidentical
transplantation may be more frequent than previously
described [11].
A synergistic combination of continuous immuno-
logic pressure mediated by donor T cells and clonal
evolution of the underlying disease can account for
the increase of GAs after transplantation, including
CN-LOH affecting critical regions such as 6p21
(HLA), 9p24 (JAK 2), 13q12 (FLT3-ITD), or
17p13.1(p53).
The FLT3-ITD mutation at relapse is frequently
associated with LOH involving chromosome 13 [28].
Increase in gene dosage of FLT3-ITD mutation is
a poor prognostic marker and increases the risk of re-
lapse [29,30]. Patients relapsing after transplant with
a homozygous FLT3-ITDmutationmay be considered
to be included in clinical trials with tyrosine kinase in-
hibitors in a combination with current therapies such
as DLIs or additional allogeneic HCT [31].In the present study a deletion in 12p13, spanning
the whole ETV6 gene region, was detected in 4 pa-
tients in the relapse sample. Rearrangements involving
chromosome 12p13 are relatively common in therapy-
related AML but uncommon in adult de novo AML
[32,33]. Several rearrangements in 12p clustered in
12p13 involving the ETV6 gene [34,35], whereas
other studies did not identify any involvement of
ETV6 in AML patients with 12p13 aberrations [36].
We also found a recurrent deletion at relapse in chro-
mosome 17p13.1 that spans the p53 gene, although we
did not perform p53 sequencing in order to detect fur-
ther mutations. Previous observation had shown a neg-
ative prognostic impact of deletion 17p in AML [37].
Infusion of alloreactive donor lymphocytes results
in a direct graft-vs-malignancy effect and constitutes
a standard treatment for disease relapse after trans-
plantation. Outcome prognostic factors after DLIs
are disease status, low tumor burden, and favorable
cytogenetics [38]. Acquired abnormalities after trans-
plantation involving critical regions, such as the
HLA locus, FLT3-ITD homozygous mutation, or ge-
nomic changes in chromosome 17p13.1 may account
for a low response rate after DLIs in these patients.
If this is indeed the case, the acquired abnor-
malities should be included in the risk assessment
and alternative treatments for selected patients relaps-
ing after allogeneic HCT must be considered.
Figure 2. Loss of mismatchedHLA on leukemic blasts from patient #14 is because of CN-LOHon chromosome 6p andwas confirmed by sequencing of
HLA-A* gene. Copy number and LOH profiles of chromosome 6 in patient #14 using SNP 6.0 mapping arrays. Pretransplant sample is represented in
green, while leukemic blast at relapse is represented in blue (A). Genome-wide analysis of isolated leukemic cells revealed a 40 Mb loss of heterozygous
SNPs (red square) on chromosome 6p, with the normal copy number, spanning thewhole HLA locus (in yellow). Partial sequence of the exon 2 of HLA-A
gene (B). Heterozygous positions (249-264) in patient sequence at the time of diagnosis, and in the donor sequence. Patient sequence in leukemic blasts
at the time of relapse shows loss of 1 allele resulting in homozygosity of the corresponding sequence.
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Hematopoietic Cell TransplantationOur results may give insights into the mechanisms
of alloresistance after transplantation, in particular in
those patients in which GAs in chromosome 6p,
12p13, 13q, or 17p13.1 are detected at relapse after
allogeneic HCT. Analysis of a larger patient cohort
is warranted to evaluate the relevance of the number,
size, and type of GAs. As has been described in the con-
text of conventional chemotherapy, specific GAs may
be of relevance for outcome after allogeneic HCT
[21]. The present study is a case-series observationalstudy and by definition does not include control sub-
jects. Additional studies, including appropriate control
groups are needed in order to further investigate the
present findings.
Large and cryptic aberrations, detected with array-
based copy number profiling, in patients undergoing
allogeneic HCT can be taken into account for refining
risk assessment and eventually for choosing a more
efficient treatment for relapse after transplantation.
In addition, the analysis of leukemic cells at relapse
Table 3. Association between Acquired Genomic Aberra-
tions (GAs) and Clinical Variables
Parameter
Number of GAs
P ValuePretransplant
Relapse
Posttransplant
Total 49 97 .037
Age
$60 (n 5 11) 30 47 .673
<60 (n 5 10) 18 50 .026
Conditioning regimen
Standard (n 5 7) 2 22‡ .04
Reduced toxicity (n 5 14) 46 75 .211
Karyotype
Normal (n 5 8) 2* 15† .062
Abnormal/complex (n 5 13) 46 82 .185
GVHD
Acute (n 5 10) 5 15 .272
Chronic (n 5 10) 8 28 .334
AML
de novo (n 5 12) 18 42 .047
Secondary (n 5 9) 30 55 .382
GVHD indicates graft-versus-host disease; AML, acute myelogenous
leukemia.
*Detected in 2 patients.
†Detected in 3 patients.
‡Detected in 4 patients.
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GAs and candidate genes with relevance to outcome
in AML patients after allogeneic transplantation.ACKNOWLEDGMENTS
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1459.e1 Biol Blood Marrow Transplant 17:1450-1459, 2011M. Waterhouse et al.APPENDIXSupplementary Table 1. Summary of Genomic Aberrations (GAs) in Patients Relapsing after Allogeneic HCT
Losses Gains CN-LOH
Total
Number of GAs
Number of
Patients with GAs
Mean Number of
GAs per Patient
Number of GAs before transplantation (number of patients) 37 (8) 8 (4) 4 (3) 49 8 2.3
Number of GAs at relapse after transplantation (number of patients) 60 (11) 27 (12) 10 (8) 97 16 4.6
HCT indicates hematopoietic cell transplantation; CN-LOH, copy-neutral loss-of-heterozygosity.
Supplementary Table 2. HLA Matching between Patient #14 and Her Respective Donor before Transplantation
HLA-A HLA-B HLA-Cw HLA-DRB1 HLA-DQB1
Patient before transplantation 02:05 03:01 35:01 37:01 04:01 06:02 01:01 15:01 05:01 06:02
Donor 02:01 03:01 35:01 37:01 02:02 04:01 01:01 15:01 05:01 05:02
Patient leukemic blast at relapse 03:01 35:01 04:01 01:01 05:01
HLA typing of leukemic blasts at relapse after transplantation from the same patient.
